Effect of Commiphora molmol Engler extract complex on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002002

Enrollment

Registered

2016-08-12

Start date

2015-01-30

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subjects will be randomized to receive Commiphora molmol Engler extract complex tablet 250mg or placebo. Subjects will orally self-adminster Commiphora molmol Engler extract compl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subject who have decreased CERAD-K(Consortium to Establish a Registry for Alzheimer’s Disease-Korean version) memory score(-1.0SD<=CERAD-K memory score) comparing to the same age and education group.

Exclusion criteria

Exclusion criteria: Subject with mental disorders such as schizophrenia, depressive disorder, drug intoxication

Design outcomes

Primary

Measure	Time frame
ADAS-cog(Alzheimer’s Disease Assessment Scale-Korean version-cognitive subscale) Total score	—

Secondary

Measure	Time frame
ADAS-cog(Alzheimer’s Disease Assessment Scale-Korean version-cognitive subscale) memory;Adverse Event	—

Countries

Korea, Republic of

Contacts

Public ContactPaik Woo

Kyung Hee University Hospital

paikjw@gmail.com

Outcome results